Transcriptomic profiling of different responder types in adults after a Priorix® vaccination

Bartholomeus, Esther; Neuter, Nicolas De; Suls, Arvid; Heijden, Sanne van der; Keersmaekers, Nina; Jansens, Hilde; Tendeloo, Viggo Van; Beutels, Philippe; Laukens, Kris; Ogunjimi, Benson; Mortier, Geert; Meysman, Pieter; Damme, Pierre Van

doi:10.1016/j.vaccine.2020.03.004

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The integrative study of a large set of biological data is referred to by the suffix—omics—such as genomics (genes), proteomics, (proteins), metabolomics (metabolites), microbiomics (microbiome) or transcriptomics (RNA), which is a fundamental part of systems biology. The application of such methodology in the development of vaccines gave birth to systems vaccinology, a young discipline that seems to be a useful tool in a number of stages of modern vaccine development strategies [ 76 ] including the prediction of vaccine response [ 77 , 78 , 79 , 80 , 81 , 82 , 83 ].…”

Section: Surrogate Markers Of Viral Response During Atimentioning

confidence: 99%

Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response

et al. 2020

View full text Add to dashboard Cite

A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials.

show abstract